In short
Lazertinib is an oral third-generation tyrosine kinase inhibitor (TKI) being studied in clinical trials for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. This article summarizes key information about ongoing clinical trials evaluating Lazertinib's efficacy, safety, and potential as a treatment option for patients with EGFR-mutant NSCLC.
At a glance
- Drug Name
- Lazertinib (also known as JNJ-73841937, YH25448)
- Drug Class
- Third-generation tyrosine kinase inhibitor (TKI)
- Target
- EGFR mutations (including exon 19 deletion, exon 21 L858R, and T790M)
- Indication
- Non-small cell lung cancer (NSCLC) with EGFR mutations
- Administration
- Oral, once daily (common dose: 240 mg)
- Clinical Trial Phases
- Phase 1, Phase 2
- Study Settings
- First-line treatment, after progression on previous EGFR-TKIs, combination with chemotherapy, neoadjuvant therapy
- Key Outcomes Measured
- Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), safety profile
- Special Populations
- Patients with brain metastases, uncommon EGFR mutations, hepatic impairment
- Ongoing Research
- Optimal dosing, biomarkers for treatment response, combination therapies, use in early-stage disease
What is Lazertinib?
Lazertinib is a new type of medication designed to treat certain forms of lung cancer. It is also known by other names such as JNJ-73841937 and YH25448. Lazertinib belongs to a class of drugs called tyrosine kinase inhibitors (TKIs), specifically a third-generation EGFR-TKI (Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor).
How Does Lazertinib Work?
Lazertinib works by targeting specific mutations in the EGFR gene that are found in some lung cancer cells. It is designed to selectively inhibit EGFR-TKI sensitizing mutations, particularly those known as exon 19 deletion or exon 21 L858R. By blocking these mutated receptors, Lazertinib can help slow down or stop the growth of cancer cells.
One of the notable features of Lazertinib is its effectiveness in patients with central nervous system (CNS) metastases, which means it can potentially treat lung cancer that has spread to the brain.
What Conditions Does Lazertinib Treat?
Lazertinib is primarily used to treat Non-Small Cell Lung Cancer (NSCLC) that has specific EGFR mutations. It is particularly useful for patients who have:
- Advanced or metastatic NSCLC with EGFR mutations (exon 19 deletion or exon 21 L858R)
- NSCLC that has progressed after treatment with first- or second-generation EGFR-TKIs
- NSCLC with T790M mutation, which often develops as a resistance mechanism to earlier generations of EGFR-TKIs
Dosage and Administration
Lazertinib is typically taken orally as a tablet. The most common dosage studied in clinical trials is 240 mg once daily. However, some studies are exploring lower doses, such as 160 mg daily, to evaluate if they can provide similar benefits with potentially fewer side effects.
It's important to note that the medication should be taken at approximately the same time each day, usually before eating a meal and in a fasting state. If a dose is missed by more than 12 hours, patients are typically advised to skip that dose and take the next one at the regular scheduled time.
Ongoing Clinical Trials
Lazertinib is being studied in various clinical trials to better understand its effectiveness and safety. Some of the ongoing research includes:
- Evaluating Lazertinib as a consolidation therapy after chemoradiation for locally advanced, unresectable NSCLC
- Studying the combination of Lazertinib with chemotherapy for patients who don't show complete response to Lazertinib alone
- Investigating Lazertinib's effectiveness in NSCLC with uncommon EGFR mutations
- Exploring Lazertinib as a neoadjuvant therapy (treatment given before surgery) for resectable NSCLC
Potential Side Effects
As with all medications, Lazertinib may cause side effects. While specific side effect profiles are still being studied in ongoing trials, common side effects of EGFR-TKIs can include:
- Skin rashes or dryness
- Diarrhea
- Fatigue
- Loss of appetite
- Nausea
Clinical trials are carefully monitoring for adverse events and evaluating the safety profile of Lazertinib. It's important for patients to report any unusual symptoms or side effects to their healthcare provider.
Future Research and Developments
Research on Lazertinib is ongoing, with several areas of focus:
- Comparing different formulations of Lazertinib to improve its effectiveness or ease of use
- Studying how liver function affects the way Lazertinib is processed in the body
- Investigating Lazertinib in combination with other cancer treatments to potentially improve outcomes
- Evaluating Lazertinib's effectiveness in earlier stages of lung cancer or as a preventive treatment after surgery
As research progresses, we may learn more about how to best use Lazertinib to help patients with NSCLC and potentially other types of cancer.